JMU scientists studied insulin-producing cells in fruit flies, finding that secretion is influenced by gut hormones, ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

Redmond, founder and CEO of Dr. Stephanie’s Supplements, showcased her products, which she described as the latest innovations in supplement options for hormone and metabolic health, including a ...

Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight ...

We are aware of reports regarding supply issues of insulin in the UK. Some of these reports are of insulins that are being discontinued and some are where there is a temporary shortage. Here’s the ...

As a result, semaglutide and its fellow glucagon-like peptide-1 drugs ... The substance stimulates the pancreas to release insulin, lowering glucose in the blood to keep blood sugar in balance. GLP-1, ...

As a result, semaglutide and its fellow glucagon-like ... pancreas to release insulin, lowering glucose in the blood to keep blood sugar in balance. GLP-1, the second incretin to be identified ...

Insulin allows cells to absorb and use glucose. In people with insulin resistance, the cells are unable to use insulin effectively. Insulin resistance occurs when cells in the body do not respond ...

The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct effects of these drugs is the subject of intense interest. Although reductions in ...

Incretins are intestinal hormones secreted in response to nutrient entry into the gut, inducing insulin secretion and inhibiting glucagon release. While this response is diminished in individuals with ...